Navigation Links
Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Date:8/11/2008

CALGARY, Aug. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with docetaxel (Taxotere(R)) in patients with advanced cancers including bladder, prostate, lung and upper gastro-intestinal. The principal investigator is Professor Hardev Pandha of the Royal Surrey Hospital, U.K.

The trial (REO 010) has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with docetaxel every three weeks. Standard dosages of docetaxel were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a further nine patients at the top dose of REOLYSIN(R) in combination with a standard dosage of docetaxel.

"We have completed the dose escalation stage of the study," said Prof. Pandha. "Patients enrolled had previously undergone significant treatment with combination chemotherapy. The combination of REOLYSIN(R) and taxotere was safe, well tolerated with no obvious toxicity related specifically to REOLYSIN(R). Efficacy of the combination was encouraging: both objective anti-tumour responses and disease stabilization were observed radiologically."

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including bladder, lung, prostate or upper gastro-intestinal cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with docetaxel. Secondary objectives include the evaluation of immune resp
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TS...d that John Docherty, president and chief operatin...6th annual Investor Summit on November 10, 2009 at...r. Docherty will provide an overview of the Compan...nd Topical Interferon Alpha-2b. The slide show po...
(Date:11/6/2009)...re-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, ... announced updated results from a Phase II study o...s metastatic to the lung in a poster presentation ...ety Meeting held in Miami Beach, Florida, from Nov...d "A Phase II Study of Intravenous REOLYSIN (Wild-...
(Date:11/5/2009)... The endangered black-footed ferre...This rare carnivore feeds on prairie dogs. The p...en entire population die-offs in towns occur. The...ented a ferret breeding program and has been relea...native habitat. Unfortunately, plague can sweep t...
(Date:11/5/2009)...wswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulle... for the quarter ended September 30, 2009. The Com...es that follow. ,, Third Quarter 2009 ,, T...1 per share for the third quarter of 2009 as compa...or the third quarter of 2008. ,, Net sales wer...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...LGARY, Oct. 4 /PRNewswire-FirstCall/ - Ms. Mary An...y of Oncolytics Biotech Inc. (TSX: ONC,NASDAQ: ONC...ny at BIO,InvestorForum 2007 on Thursday, October ...he Palace Hotel in San Francisco from October 9-11...tion is available on the,company,s website at htt...
...esentation to Include the Recently Released Strong...tudy using the AppyScore Human Appendicitis ...STLE ROCK, Colo., Oct. 4 AspenBio Pharma,Inc. (Na...ny dedicated to the,development of novel drugs and...ted to present at the Edgewater Research Investor ...
...MERSET, N.J., Oct. 4 Alfacell Corporation,(Nasdaq... executive vice,president, chief financial officer... of the company,s product development programs at ... at the Palace Hotel in San Francisco. A live aud...n,Alfacell,s Web site at http://www.alfacell.com ...
Other Biology Technology:Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007 2AspenBio Pharma to Present the Edgewater Research Investor Conference 2Alfacell to Present at BIO InvestorForum 2007 2
(Date:11/8/2009)...N - (Nov. 8, 2009) The loss of a gene through del...ciated with significant abnormalities in learning ... by Baylor College of Medicine ( www.bcm.edu ) in ... Nature Genetics . , "This research goes about 9...a specific group of individuals to this gene," sai...
(Date:11/6/2009)...ling ants generally live in harmony with their arb...hey run out of space in their trees of choice, the... The research, published in the November issue of...nt that ants bore into live trees, and it reopens ... ants and plants. , Ants and certain species of ...
(Date:11/5/2009)..., Conn.Researchers at Yale University have develop...dy,s immune response to HIV and HIV-infected cells...ngs, published online in the Journal of the Ameri...utic approaches for these diseases. , The molec...ng HIV" (ARM-H) and "antibody-recruiting molecule ...
Breaking Biology News(10 mins):Developmental delay could stem from nicotinic receptor deletion 2Ants are friendly to some trees, but not others 2New synthetic molecules trigger immune response to HIV and prostate cancer 2UD to host conference on Ethics of Climate Change 10413 1UD to host conference on Ethics of Climate Change 10413 2CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 1CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 2CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 3CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 4Scientists Find New Key to Lupus 59752 1Scientists Find New Key to Lupus 59752 2
...interface between nanotechnology and neuroscience,...r silicon nanowires to detect, stimulate, and inhi... live mammalian neurons. , Harvard chemist Charle... of nanowires and neurons this week in the journal...napses between nanoelectronic devices and individu...
...der certain conditions, many common household clea...evels that may lead to health risks, according to ...lifornia, Berkeley, and Lawrence Berkeley National...utants ?and to the secondary pollutants formed whe...regulatory guidelines when a large surface is clea...
...positive subjects shows that HIV in the brain and ...om HIV that lives in the blood and peripheral tiss...ng the study subjects was correlated with the pres...gene. , The study appears in the July 2006 issu... staff research associate at SFVAMC and a postdoct...
Other Biology News:Nanowire arrays can detect signals along individual neurons 2Many cleaners, air fresheners may pose health risks when used indoors 2Many cleaners, air fresheners may pose health risks when used indoors 3Many cleaners, air fresheners may pose health risks when used indoors 4Many cleaners, air fresheners may pose health risks when used indoors 5Many cleaners, air fresheners may pose health risks when used indoors 6Viral genetic differences are possible key to HIV dementia 2Viral genetic differences are possible key to HIV dementia 3
Mouse Anti-TCR V beta 5 Monoclonal Antibody, Unconjugated, Clone MH3-2 from BD Biosciences Pharmingen
Mouse Anti-Cystatin A Monoclonal Antibody, Unconjugated, Clone WR-23/2/3/3 from Sigma-Aldrich
Human COX-2 ELISA Kit from Invitrogen
...ease of use and flexibility of the BDTM LSR, the f...es the BDTM LSR II. The BD LSR II has performance...in a benchtop analyzer. Free up your high-perform...t require a UV laser to the BD LSR II. The BD LSR ...
Biology Products: